ArticleJournal of bacteriology2010
Xer1-mediated site-specific DNA inversions and excisions in Mycoplasma agalactiae.
Article in Journal of bacteriology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Sheep Infection Trials with 'Phase-Locked' Vpma Expression Variants ofMicroorganisms · 2022Article
- Predominant Single Stable VpmaV Expression in Strain GM139 and Major Differences withAnimals : an open access journal from MDPI · 2022Article
- Mycoplasma agalactiae ST35: a new sequence type with a minimal accessory genome primarily affecting goats.BMC veterinary research · 2022Article
- Invertible promoters mediate bacterial phase variation, antibiotic resistance, and host adaptation in the gut.Science (New York, N.Y.) · 2019Article
- Vpma phase variation is important for survival and persistence of Mycoplasma agalactiae in the immunocompetent host.PLoS pathogens · 2017Article
- Article
- In vitro and in vivo cell invasion and systemic spreading of Mycoplasma agalactiae in the sheep infection model.International journal of medical microbiology : IJMM · 2014Article
- Interaction of the putative tyrosine recombinases RipX (UU145), XerC (UU222), and CodV (UU529) of Ureaplasma parvum serovar 3 with specific DNA.FEMS microbiology letters · 2013Article
- Role of Vpma phase variation in Mycoplasma agalactiae pathogenesis.FEMS immunology and medical microbiology · 2012Article
- Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains.BMC microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Surface antigen variation in Mycoplasma agalactiae, the etiologic agent of contagious agalactia in sheep and goats, is governed by site-specific recombination within the vpma multigene locus encoding the Vpma family of variable surface lipoproteins. This high-frequency Vpma phase switching was previously shown to be mediated by a Xer1 recombinase encoded adjacent to the vpma locus. In this study, it was demonstrated in Escherichia coli that the Xer1 recombinase is responsible for catalyzing vpma gene inversions between recombination sites (RS) located in the 5'-untranslated region (UTR) in all six vpma genes, causing cleavage and strand exchange within a 21-bp conserved region that serves as a recognition sequence. It was further shown that the outcome of the site-specific recombination event depends on the orientation of the two vpma RS, as direct or inverted repeats. While recombination between inverted vpma RS led to inversions, recombination between direct repeat vpma RS led to excisions. Using a newly developed excision assay based on the lacZ reporter system, we were able to successfully demonstrate under native conditions that such Xer1-mediated excisions can indeed also occur in the M. agalactiae type strain PG2, whereas they were not observed in the control xer1-disrupted VpmaY phase-locked mutant (PLMY), which lacks Xer1 recombinase. Unless there are specific regulatory mechanisms preventing such excisions, this might be the cost that the pathogen has to render at the population level for maintaining this high-frequency phase variation machinery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.